Self-DNA, STING-dependent signaling and the origins of autoinflammatory disease

Current Opinion in Immunology

Volumn 31, Issue , 2014, Pages 121-126

  Ahn, Jeonghyun ^a   Barber, Glen N ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; DEOXYRIBONUCLEASE; DEOXYRIBONUCLEASE II; DNA; INTERFERON; INTERFERON REGULATORY FACTOR 3; MEMBRANE PROTEIN; PROTEIN STING; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; CYTOKINE; MPYS PROTEIN, HUMAN; TUMOR PROTEIN;

AICARDI GOUTIERES SYNDROME; ANTIBODY DETECTION; AUTOINFLAMMATORY DISEASE; AUTOPHAGY; B LYMPHOCYTE; BINDING AFFINITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA DEGRADATION; HOST RESISTANCE; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PLASMACYTOID DENDRITIC CELL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE; ANIMAL; AUTOIMMUNE DISEASE; IMMUNOLOGY; INFLAMMATION; NEOPLASM; PATHOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; CYTOKINES; DNA; HUMANS; INFLAMMATION; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84910040154     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2014.10.009     Document Type: Review

References (46)

1. Ishikawa H., Barber G.N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008, 455:674-678.
2. Ishikawa H., Ma Z., Barber G.N. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009, 461:788-792.
3. Burdette D.L., Monroe K.M., Sotelo-Troha K., Iwig J.S., Eckert B., Hyodo M., Hayakawa Y., Vance R.E. STING is a direct innate immune sensor of cyclic di-GMP. Nature 2011, 478:515-518.
4. Cai X., Chiu Y.H., Chen Z.J. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell 2014, 54:289-296.
5. Ahn J., Gutman D., Saijo S., Barber G.N. STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A 2012, 109:19386-19391.
6. Ahn J., Xia T., Konno H., Konno K., Ruiz P., Barber G.N. Inflammation-driven carcinogenesis is mediated through STING. Nat Commun 2014, 5:5166.
7. Liu Y., Jesus A.A., Marrero B., Yang D., Ramsey S.E., Montealegre Sanchez G.A., Tenbrock K., Wittkowski H., Jones O.Y., Kuehn H.S., et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 2014, 371:507-518.
8. Gall A., Treuting P., Elkon K.B., Loo Y.M., Gale M., Barber G.N., Stetson D.B. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 2012, 36:120-131.
9. Ahn J., Ruiz P., Barber G.N. Intrinsic self-DNA triggers inflammatory disease dependent on STING. J Immunol 2014.
10. Blasius A.L., Beutler B. Intracellular toll-like receptors. Immunity 2010, 32:305-315.
11. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
12. Bauernfeind F., Hornung V. Of inflammasomes and pathogens - sensing of microbes by the inflammasome. EMBO Mol Med 2013, 5:814-826.
13. Woodward J.J., Iavarone A.T., Portnoy D.A. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science 2010, 328:1703-1705.
14. Abe T., Harashima A., Xia T., Konno H., Konno K., Morales A., Ahn J., Gutman D., Barber G.N. STING recognition of cytoplasmic DNA instigates cellular defense. Mol Cell 2013, 50:5-15.
15. Sun L., Wu J., Du F., Chen X., Chen Z.J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013, 339:786-791.
16. Konno H., Konno K., Barber G.N. Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling. Cell 2013, 155:688-698.
17. Watson R.O., Manzanillo P.S., Cox J.S. Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell 2012, 150:803-815.
18. Maringer K., Fernandez-Sesma A. Message in a bottle: lessons learned from antagonism of STING signalling during RNA virus infection. Cytokine Growth Factor Rev 2014.
19. Rumore P.M., Steinman C.R. Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J Clin Invest 1990, 86:69-74.
20. Crow M.K. Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol 2007, 316:359-386.
21. Tsokos G.C. Systemic lupus erythematosus. N Engl J Med 2011, 365:2110-2121.
22. Smith S., Jefferies C. Role of DNA/RNA sensors and contribution to autoimmunity. Cytokine Growth Factor Rev 2014.
23. Kawane K., Fukuyama H., Kondoh G., Takeda J., Ohsawa Y., Uchiyama Y., Nagata S. Requirement of DNase II for definitive erythropoiesis in the mouse fetal liver. Science 2001, 292:1546-1549.
24. Morita M., Stamp G., Robins P., Dulic A., Rosewell I., Hrivnak G., Daly G., Lindahl T., Barnes D.E. Gene-targeted mice lacking the Trex1 (DNase III) 3'→5' DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol 2004, 24:6719-6727.
25. Napirei M., Karsunky H., Zevnik B., Stephan H., Mannherz H.G., Moroy T. Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat Genet 2000, 25:177-181.
26. Crispin J.C., Hedrich C.M., Tsokos G.C. Gene-function studies in systemic lupus erythematosus. Nat Rev Rheumatol 2013, 9:476-484.
27. Martinez Valle F., Balada E., Ordi-Ros J., Vilardell-Tarres M. DNase 1 and systemic lupus erythematosus. Autoimmun Rev 2008, 7:359-363.
28. Nagata S. Apoptosis and autoimmune diseases. Ann N Y Acad Sci 2010, 1209:10-16.
29. Kawane K., Fukuyama H., Yoshida H., Nagase H., Ohsawa Y., Uchiyama Y., Okada K., Iida T., Nagata S. Impaired thymic development in mouse embryos deficient in apoptotic DNA degradation. Nat Immunol 2003, 4:138-144.
30. Kawane K., Ohtani M., Miwa K., Kizawa T., Kanbara Y., Yoshioka Y., Yoshikawa H., Nagata S. Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 2006, 443:998-1002.
31. Malickova K., Duricova D., Bortlik M., Hruskova Z., Svobodova B., Machkova N., Komarek V., Fucikova T., Janatkova I., Zima T., et al. Impaired deoxyribonuclease I activity in patients with inflammatory bowel diseases. Autoimmune Dis 2011, 2011:945861.
32. Lee-Kirsch M.A., Gong M., Chowdhury D., Senenko L., Engel K., Lee Y.A., de Silva U., Bailey S.L., Witte T., Vyse T.J., et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007, 39:1065-1067.
33. Olivieri I., Cattalini M., Tonduti D., La Piana R., Uggetti C., Galli J., Meini A., Tincani A., Moratto D., Fazzi E., et al. Dysregulation of the immune system in Aicardi-Goutieres syndrome: another example in a TREX1-mutated patient. Lupus 2013, 22:1064-1069.
34. Rice G.I., Forte G.M., Szynkiewicz M., Chase D.S., Aeby A., Abdel-Hamid M.S., Ackroyd S., Allcock R., Bailey K.M., Balottin U., et al. Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol 2013, 12:1159-1169.
35. Abe J., Nakamura K., Nishikomori R., Kato M., Mitsuiki N., Izawa K., Awaya T., Kawai T., Yasumi T., Toyoshima I., et al. A nationwide survey of Aicardi-Goutieres syndrome patients identifies a strong association between dominant TREX1 mutations and chilblain lesions: Japanese cohort study. Rheumatology (Oxford) 2014, 53:448-458.
36. Pereira-Lopes S., Celhar T., Sans-Fons G., Serra M., Fairhurst A.M., Lloberas J., Celada A. The exonuclease trex1 restrains macrophage proinflammatory activation. J Immunol 2013, 191:6128-6135.
37. Stetson D.B., Ko J.S., Heidmann T., Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008, 134:587-598.
38. Yang Y.G., Lindahl T., Barnes D.E. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 2007, 131:873-886.
39. Ablasser A., Hemmerling I., Schmid-Burgk J.L., Behrendt R., Roers A., Hornung V. TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner. J Immunol 2014, 192:5993-5997.
40. Gehrke N., Mertens C., Zillinger T., Wenzel J., Bald T., Zahn S., Tuting T., Hartmann G., Barchet W. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity 2013, 39:482-495.
41. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol 2012, 30:677-706.
42. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
43. Boffetta P., Jourenkova N., Gustavsson P. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 1997, 8:444-472.
44. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther 1992, 54:63-128.
45. Cataisson C., Salcedo R., Hakim S., Moffitt B.A., Wright L., Yi M., Stephens R., Dai R.M., Lyakh L., Schenten D., et al. IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis. J Exp Med 2012, 209:1689-1702.
46. Yarbrough M.L., Zhang K., Sakthivel R., Forst C.V., Posner B.A., Barber G.N., White M.A., Fontoura B.M. Primate-specific miR-576-3p sets host defense signalling threshold. Nat Commun 2014, 5:4963.